The Food and Drug Administration said today it approved a next-generation silicone breast implant from Mentor, a unit of New Brunswick-based Johnson & Johnson. The company's MemoryShape breast implant uses a cross-linking gel design that the FDA ...

This morning, Johnson & Johnson (JNJ) announced it would buy Aragon Pharmaceuticals for as much as $1 billion. Aragon Pharmaceuticals is a privately held company and as part of the deal would receive $650 million in cash upfront and an additional ...

In the following video, Fool contributor Maxx Chatsko discusses the recent investment by Johnson & Johnson (NYSE: JNJ ) into a tiny start-up called Second Genome.

China's food and drug safety regulator is taking Johnson & Johnson to task with claims that the US company has a shoddy quality-control system (link in Chinese).

Speculative players have been taking sides on blue chip Johnson & Johnson (NYSE:JNJ), automaker General Motors Company (NYSE:GM), and Finnish telecom concern Nokia Corporation (ADR) (NYSE:NOK), according to data from the major options ...

Johnson & Johnson has agreed to buy Aragon Pharmaceuticals Inc., a privately held company that is developing treatments for hormonally driven cancers, in a deal valued at up to $1 billion.

SAN DIEGO, CA, Jun 17, 2013 (Marketwired via COMTEX) -- Aragon Pharmaceuticals Inc., a leader in developing drugs for hormone driven cancers, today announced a definitive agreement with Johnson & Johnson whereby Aragon will be acquired for $650 ...

On Monday, healthcare product company, Johnson & Johnson (JNJ ) announced that it will acquire Aragon Pharmaceuticals. Aragon, which is a private company that is currently in a mid-stage clinical trial for a prostate cancer drug will be acquired by JNJ ...

(Reuters) - Johnson & Johnson said it would pay up to $1 billion for Aragon Pharmaceuticals and its experimental drugs for prostate cancer, to bolster J&J's role in the field after it acquired another experimental prostate-cancer treatment four years ...

Johnson & Johnson sold 25.4 million shares of Elan Corp., ending a relationship started four years ago to develop the Alzheimer's disease drug bapineuzumab.